CEAC预处理后行自体造血干细胞移植对非霍奇金淋巴瘤患者的疗效评价

杨懿春; 岑雪波; 罗小华; 王欣; 唐晓琼; 肖青; 张红宾; 陈建斌; 刘林; 王利

doi:10.16016/j.1000-5404.201905099

您当前的位置：

首页 >

文章列表页 >

CEAC预处理后行自体造血干细胞移植对非霍奇金淋巴瘤患者的疗效评价

专题报道：造血干细胞移植与细胞治疗 | 更新时间：2026-01-09

- CEAC预处理后行自体造血干细胞移植对非霍奇金淋巴瘤患者的疗效评价
- Efficacy of CEAC regimen before autologous hematopoietic stem cell transplantation for non-Hodgkin lymphoma: analysis of 102 cases
- 第三军医大学学报 2019年41卷第23期页码：2272-2279
- 作者机构：
- 作者简介：
- 基金信息：
  
  重庆市科卫联合医学科研项目重点项目(2018ZDXM001)
- DOI：10.16016/j.1000-5404.201905099
  中图分类号：
- 收稿：2019-05-15，
  
  纸质出版：2019-12-25
- 稿件说明：
移动端阅览
杨懿春, 岑雪波, 罗小华, 等. CEAC预处理后行自体造血干细胞移植对非霍奇金淋巴瘤患者的疗效评价[J]. 第三军医大学学报, 2019,41(23):2272-2279.

Yichun YANG, Xuebo CEN, Xiaohua LUO, et al. Efficacy of CEAC regimen before autologous hematopoietic stem cell transplantation for non-Hodgkin lymphoma: analysis of 102 cases[J]. Journal of Third Military Medical University, 2019, 41(23): 2272-2279.
杨懿春, 岑雪波, 罗小华, 等. CEAC预处理后行自体造血干细胞移植对非霍奇金淋巴瘤患者的疗效评价[J]. 第三军医大学学报, 2019,41(23):2272-2279. DOI： 10.16016/j.1000-5404.201905099.

Yichun YANG, Xuebo CEN, Xiaohua LUO, et al. Efficacy of CEAC regimen before autologous hematopoietic stem cell transplantation for non-Hodgkin lymphoma: analysis of 102 cases[J]. Journal of Third Military Medical University, 2019, 41(23): 2272-2279. DOI： 10.16016/j.1000-5404.201905099.

摘要

Abstract

Objective

To investigate the clinical efficacy and adverse reactions of CEAC conditioning regimen combined with autologous hematopoietic stem cell transplantation for treatment of non-Hodgkin lymphoma.

Methods

We conducted a retrospective analysis of 102 patients with non-Hodgkin lymphoma

who underwent autologous hematopoietic stem cell transplantation after CEAC conditioning regimen in our hospital from 2011 to 2017. The factors affecting the patients' survival

clinical efficacy of the treatment

neutrophil and platelet reconstitution time

and adverse events associated with the conditioning regimen were analyzed.

Results

Hematopoietic reconstruction was achieved successfully in 100 of the 102 patients. The median time of neutrophil and platelet reconstitution time was 10 d (7~17 d) and 12 d (7~33 d) in these cases

respectively. The main adverse reactions included nausea

vomit

fever

liver toxicity and diarrhea. The patients were followed up for a median of 42 months

during which disease progression occurred in 25 (24.5%) cases; death occurred in 18 (17.6%) cases

and 9 (8.8%) of these cases resulted from disease progression. The overall 3-year survival rate of the patients was 81.3%

with an overall 3-year progression-free survival rate of 77.5%. Univariate

analysis showed that the disease type was a prognostic factor for the overall survival (

0.001) and progression-free survival (

0.001)

and IPI score was a prognostic factor for progression-free survival (

=0.041). Multivariate analysis showed that the disease type (

=0.144

95%

: 0.052~0.400

0.001) was an independent prognostic factor for the overall survival; the disease type (

=0.291

95%

: 0.133~0.637

=0.002) and the pretransplant status (

=1.940

95%

: 1.192~3.159

=0.008) were independent prognostic factors for progression-free survival. The toxic reactions related with the conditioning regimen included nausea

vomiting

diarrhea

fever

and infections

and the transplant-related mortality rate was 1.96%.

Conclusion

CEAC conditioning regimen can achieve a good efficacy with tolerable adverse reactions in patients undergoing autologous hematopoietic stem cell transplantation for non-Hodgkin lymphoma.

关键词

Keywords

references

CHIHARA D NASTOUPIL L J WILLIAMS J N New insights into the epidemiology of non-Hodgkin lymphoma and implications for therapy Expert Rev Anticancer Ther 2015 15 5 531 544 10.1586/14737140.2015.1023712 CHIHARA D, NASTOUPIL L J, WILLIAMS J N, et al . New insights into the epidemiology of non-Hodgkin lymphoma and implications for therapy[J ] . Expert Rev Anticancer Ther, 2015, 15(5): 531-544. DOI:10.1586/14737140.2015.1023712.

SAKELLARI I MALLOURI D BATSIS I Carmustine, etoposide, cytarabine and melphalan versus a newly designed intravenous busulfan-based Busulfex, etoposide and melphalan conditioning regimen for autologous hematopoietic cell transplant: a retrospective matched-pair analysis in advanced Hodgkin and non-Hodgkin lymphomas Leuk Lymphoma 2015 56 11 3071 3081 10.3109/10428194.2015.1028054 SAKELLARI I, MALLOURI D, BATSIS I, et al . Carmustine, etoposide, cytarabine and melphalan versus a newly designed intravenous busulfan-based Busulfex, etoposide and melphalan conditioning regimen for autologous hematopoietic cell transplant: a retrospective matched-pair analysis in advanced Hodgkin and non-Hodgkin lymphomas[J ] . Leuk Lymphoma, 2015, 56(11): 3071-3081. DOI:10.3109/10428194.2015.1028054.

朱雄增 WHO(2008)恶性淋巴瘤分类解读诊断病理学杂志 2009 16 4 241 245 10.3969/j.issn.1007-8096.2009.04.01 朱雄增.WHO(2008)恶性淋巴瘤分类解读[J].诊断病理学杂志, 2009, 16(4):241-245. DOI: 10.3969/j.issn.1007-8096.2009.04.01.

ZHU X Z Interpretation of malignant lymphoma classification WHO(2008) Chin J Diagn Pathol 2009 16 4 241 245 10.3969/j.issn.1007-8096.2009.04.01 ZHU X Z. Interpretation of malignant lymphoma classification WHO(2008)[J]. Chin J Diagn Pathol, 2009, 16(4): 241-245. DOI: 10.3969/j.issn.1007-8096.2009.04.01.

LIU H RICH E S GODLEY L Reduced-intensity conditioning with combined haploidentical and cord blood transplantation results in rapid engraftment, low GVHD, and durable remissions Blood 2011 118 24 6438 6445 10.1182/blood-2011-08-372508 LIU H, RICH E S, GODLEY L, et al . Reduced-intensity conditioning with combined haploidentical and cord blood transplantation results in rapid engraftment, low GVHD, and durable remissions[J ] . Blood, 2011, 118(24): 6438-6445. DOI:10.1182/blood-2011-08-372508.

CHUNG A E SHOENBILL K MITCHELL S A Patient free text reporting of symptomatic adverse events in cancer clinical research using the national cancer institute's patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE) J Am Med Inform Assoc 2019 26 4 276 285 10.1093/jamia/ocy169 CHUNG A E, SHOENBILL K, MITCHELL S A, et al . Patient free text reporting of symptomatic adverse events in cancer clinical research using the national cancer institute's patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE)[J ] . J Am Med Inform Assoc, 2019, 26(4): 276-285. DOI:10.1093/jamia/ocy169.

CHESON B D PFISTNER B JUWEID M E Revised response criteria for malignant lymphoma J Clin Oncol 2007 25 5 579 586 10.1200/jco.2006.09.2403 CHESON B D, PFISTNER B, JUWEID M E, et al . Revised response criteria for malignant lymphoma[J ] . J Clin Oncol, 2007, 25(5): 579-586. DOI:10.1200/jco.2006.09.2403.

STIFF P J UNGER J M COOK J R Autologous transplantation as consolidation for aggressive non-Hodgkin's lymphoma N Engl J Med 2013 369 18 1681 1690 10.1056/NEJMoa1301077 STIFF P J, UNGER J M, COOK J R, et al . Autologous transplantation as consolidation for aggressive non-Hodgkin's lymphoma[J ] . N Engl J Med, 2013, 369(18): 1681-1690. DOI:10.1056/NEJMoa1301077.

GUPTA A GOKARN A RAJAMANICKAM D Lomustine, cytarabine, cyclophosphamide, etoposide—An effective conditioning regimen in autologous hematopoietic stem cell transplant for primary refractory or relapsed lymphoma: Analysis of toxicity, long-term outcome, and prognostic factors J Cancer Res Ther 2018 14 5 926 933 10.4103/0973-1482.181183 GUPTA A, GOKARN A, RAJAMANICKAM D, et al . Lomustine, cytarabine, cyclophosphamide, etoposide—An effective conditioning regimen in autologous hematopoietic stem cell transplant for primary refractory or relapsed lymphoma: Analysis of toxicity, long-term outcome, and prognostic factors[J ] . J Cancer Res Ther, 2018, 14(5): 926-933. DOI:10.4103/0973-1482.181183.

SHI Y W LIU P ZHOU S Y Comparison of CBV, BEAM and BEAC high-dose chemotherapy followed by autologous hematopoietic stem cell transplantation in non-Hodgkin lymphoma: Efficacy and toxicity Asia Pac J Clin Oncol 2017 13 5 e423 e429 10.1111/ajco.12610 SHI Y W, LIU P, ZHOU S Y, et al . Comparison of CBV, BEAM and BEAC high-dose chemotherapy followed by autologous hematopoietic stem cell transplantation in non-Hodgkin lymphoma: Efficacy and toxicity[J ] . Asia Pac J Clin Oncol, 2017, 13(5): e423-e429. DOI:10.1111/ajco.12610.

勇威本郑文卫燕中、高度恶性T和B细胞淋巴瘤的临床比较中华血液学杂志 2002 23 8 428 429 http://d.old.wanfangdata.com.cn/Periodical/zhxyx200208009 勇威本, 郑文, 卫燕, 等.中、高度恶性T和B细胞淋巴瘤的临床比较[J].中华血液学杂志, 2002, 23(8): 428-429.

YONG W B ZHENG W WEI Y Clinical comparison of middle-and highly malignant T-and B-cell lymphoma Chin J Hematol 2002 23 8 428 429 http://d.old.wanfangdata.com.cn/Periodical/zhxyx200208009 YONG W B, ZHENG W, WEI Y, et al . Clinical comparison of middle-and highly malignant T-and B-cell lymphoma[J ] . Chin J Hematol, 2002, 23(8): 428-429.

贺莹利妥昔单抗联合自体造血干细胞移植治疗B细胞非霍奇金淋巴瘤患者的疗效观察中国民康医学 2019 31 7 62 64 http://d.old.wanfangdata.com.cn/Periodical/zgmzyxzz201907029 贺莹.利妥昔单抗联合自体造血干细胞移植治疗B细胞非霍奇金淋巴瘤患者的疗效观察[J].中国民康医学, 2019, 31(7): 62-64.

HE Y Effect of rituximab combined with autologous hematopoietic stem cell transplantation on patients with B cell non-Hodgkin lymphoma Med J Chin People Health 2019 31 7 62 64 http://d.old.wanfangdata.com.cn/Periodical/zgmzyxzz201907029 HE Y. Effect of rituximab combined with autologous hematopoietic stem cell transplantation on patients with B cell non-Hodgkin lymphoma[J]. Med J Chin People Health, 2019, 31(7): 62-64.

D'AMORE F RELANDER T LAURITZSEN G F Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01 J Clin Oncol 2012 30 25 3093 3099 10.1200/jco.2011.40.2719 D'AMORE F, RELANDER T, LAURITZSEN G F, et al . Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01[J ] . J Clin Oncol, 2012, 30(25): 3093-3099. DOI:10.1200/jco.2011.40.2719.

CORRADINI P TARELLA C ZALLIO F Long-term follow-up of patients with peripheral T-cell lymphomas treated up-front with high-dose chemotherapy followed by autologous stem cell transplantation Leukemia 2006 20 9 1533 1538 10.1038/sj.leu.2404306 CORRADINI P, TARELLA C, ZALLIO F, et al . Long-term follow-up of patients with peripheral T-cell lymphomas treated up-front with high-dose chemotherapy followed by autologous stem cell transplantation[J ] . Leukemia, 2006, 20(9): 1533-1538. DOI:10.1038/sj.leu.2404306.

蒲欣陈洁平自体造血干细胞移植治疗高危难治淋巴瘤生存分析重庆医学 2016 45 12 1620 1623, 1626 10.3969/j.issn.1671-8348.2016.12.011 蒲欣, 陈洁平.自体造血干细胞移植治疗高危难治淋巴瘤生存分析[J].重庆医学, 2016, 45(12):1620-1623, 1626. DOI: 10.3969/j.issn.1671-8348.2016.12.011.

PU X CHEN J P Survival analysis of patients with high risk refractory lymphoma treated by autologous hematopoietic stem cell transplantation Chongqing Med 2016 45 12 1620 1623, 1626 10.3969/j.issn.1671-8348.2016.12.011 PU X, CHEN J P. Survival analysis of patients with high risk refractory lymphoma treated by autologous hematopoietic stem cell transplantation[J]. Chongqing Med, 2016, 45(12): 1620-1623, 1626. DOI: 10.3969/j.issn.1671-8348.2016.12.011.

PYTLÍK R BELADA D KUBÁ C ˇ KOVÁ K Treatment of high-risk aggressive B-cell non-Hodgkin lymphomas with rituximab, intensive induction and high-dose consolidation: long-term analysis of the R-MegaCHOP-ESHAP-BEAM Trial Leuk Lymphoma 2015 56 1 57 64 10.3109/10428194.2014.904509 PYTLÍK R, BELADA D, KUBÁ C ˇ KOVÁ K, et al . Treatment of high-risk aggressive B-cell non-Hodgkin lymphomas with rituximab, intensive induction and high-dose consolidation: long-term analysis of the R-MegaCHOP-ESHAP-BEAM Trial[J ] . Leuk Lymphoma, 2015, 56(1): 57-64. DOI:10.3109/10428194.2014.904509.

YOON J H KIM J W JEON Y W Role of frontline autologous stem cell transplantation in young, high-risk diffuse large B-cell lymphoma patients Korean J Intern Med 2015 30 3 362 371 10.3904/kjim.2015.30.3.362 YOON J H, KIM J W, JEON Y W, et al . Role of frontline autologous stem cell transplantation in young, high-risk diffuse large B-cell lymphoma patients[J ] . Korean J Intern Med, 2015, 30(3): 362-371. DOI:10.3904/kjim.2015.30.3.362.

YIN J WEI J XU J H Autologous stem cell transplantation as the first-line treatment for peripheral T cell lymphoma: results of a comprehensive meta-analysis Acta Haematol 2014 131 2 114 125 10.1159/000353778 YIN J, WEI J, XU J H, et al . Autologous stem cell transplantation as the first-line treatment for peripheral T cell lymphoma: results of a comprehensive meta-analysis[J ] . Acta Haematol, 2014, 131(2): 114-125. DOI:10.1159/000353778.

周沙曾东风张曦 CEAC预处理方案在自体造血干细胞移植治疗恶性淋巴瘤临床观察中国输血杂志 2015 28 11 1300 1303 10.13303/j.cjbt.issn.1004-549x.2015.11.002 周沙, 曾东风, 张曦, 等. CEAC预处理方案在自体造血干细胞移植治疗恶性淋巴瘤临床观察[J].中国输血杂志, 2015, 28(11):1300-1303. DOI: 10.13303/j.cjbt.issn. 1004-549x.2015.11.002.

ZHOU S ZENG D F ZHANG X Clinical observation of CEAC preconditioned regimens in autologous hematopoietic stem cell transplantation(ASCT) for patients with malignant lymphoma Chin J Blood Transfus 2015 28 11 1300 1303 10.13303/j.cjbt.issn.1004-549x.2015.11.002 ZHOU S, ZENG D F, ZHANG X, et al . Clinical observation of CEAC preconditioned regimens in autologous hematopoietic stem cell transplantation(ASCT) for patients with malignant lymphoma[J ] . Chin J Blood Transfus, 2015, 28(11): 1300-1303. DOI:10.13303/j.cjbt.issn.1004-549x. 2015.11.002.

浏览量

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

自体造血干细胞移植治疗复发、难治性经典型霍奇金淋巴瘤的疗效观察

非霍奇金淋巴瘤CHOP样方案化疗后继发类固醇糖尿病的相关危险因素分析

西达本胺维持治疗预防外周T细胞淋巴瘤自体造血干细胞移植术后复发的临床观察

自体造血干细胞移植期间腹泻患者艰难梭菌感染及其影响因素分析

异基因造血干细胞移植术治疗自体造血干细胞移植术后复发的恶性淋巴瘤17例效果分析